In addition to dapagliflozin, the recently published EMPEROR-Preserved clinical trial explored the effect of empagliflozin (another SGLT2 inhibitor) on the primary composite endpoint of HF hospitalization or cardiovascular death in patients with HF and an EF of >40% (157). This evidence concerns the gene SLC5A2 and hydrops fetalis.